Methods of enhancing functioning of the upper gastrointestinal tract
CA 2289652 C · Owner: Drucker, Daniel J. · Inventors: Drucker, Daniel J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the upper gastrointestinal tract including the esophagus and stomach. In particular it has now been , demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of the upper gastrointestinal tract. Thus the invention , provides methods of proliferating the upper gastrointestinal tract in a subject in need thereof. Further, the methods of the invention are useful to treat or prevent inflammatory conditions of the upper gastrointestinal tract including inflammatory diseases. GLP-2 stimulates the growth of upper gastrointestinal tissue …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed May 15, 1998 and granted February 28, 2012. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended May 15, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by May 15, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.